A Combination Therapy Targeting Endoglin and VEGF-A Prevents Subretinal Fibro-Neovascularization Caused by Induced Müller Cell Disruption | Zendy

Weiyong Shen | Zendy; Sora Lee | Zendy; Michelle Yam | Zendy; Ling Zhu | Zendy; Ting Zhang | Zendy; Victoria Pye | Zendy; Ashish Easow Mathai | Zendy; Keiichi Shibagaki | Zendy; Jinzhong Zhang | Zendy; Takeshi Matsugi | Zendy; Mark C. Gillies | Zendy

Open Access

A Combination Therapy Targeting Endoglin and VEGF-A Prevents Subretinal Fibro-Neovascularization Caused by Induced Müller Cell Disruption

Author(s) -

Weiyong Shen,

Sora Lee,

Michelle Yam,

Ling Zhu,

Ting Zhang,

Victoria Pye,

Ashish Easow Mathai,

Keiichi Shibagaki,

Jinzhong Zhang,

Takeshi Matsugi,

Mark C. Gillies

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-25628

Subject(s) - neovascularization , vegf receptors , endoglin , cancer research , ophthalmology , medicine , chemistry , angiogenesis , microbiology and biotechnology , biology , stem cell , cd34

Subretinal fibroneovascularization is one of the most common causes of vision loss in neovascular AMD (nAMD). Anti-VEGF therapy effectively inhibits vascular leak and neovascularization but has little effect on fibrosis. This study aimed to identify a combination therapy to concurrently inhibit subretinal neovascularization and prevent fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research